| 000 | 01675 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250518060141.0 | ||
| 264 | 0 | _c20201020 | |
| 008 | 202010s 0 0 eng d | ||
| 022 | _a2045-2322 | ||
| 024 | 7 |
_a10.1038/s41598-019-49251-5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHardy-Werbin, Max | |
| 245 | 0 | 0 |
_aReal-world data on T-DM1 efficacy - results of a single-center retrospective study of HER2-positive breast cancer patients. _h[electronic resource] |
| 260 |
_bScientific reports _c09 2019 |
||
| 300 |
_a12760 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMaytansine _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xmetabolism |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aTrastuzumab _xadministration & dosage |
| 700 | 1 | _aQuiroga, Vanesa | |
| 700 | 1 | _aCirauqui, Beatriz | |
| 700 | 1 | _aRomeo, Margarita | |
| 700 | 1 | _aFelip, Eudald | |
| 700 | 1 | _aTeruel, Iris | |
| 700 | 1 | _aGarcia, Juan Jose | |
| 700 | 1 | _aErasun, Carlos | |
| 700 | 1 | _aEspaña, Sofia | |
| 700 | 1 | _aCucurull, Marc | |
| 700 | 1 | _aMontprade, Elisabeth | |
| 700 | 1 | _aPardo, Juan Carlos | |
| 700 | 1 | _aCarballo, Dania | |
| 700 | 1 | _aVelarde, Jose Maria | |
| 700 | 1 | _aMargeli, Mireia | |
| 773 | 0 |
_tScientific reports _gvol. 9 _gno. 1 _gp. 12760 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/s41598-019-49251-5 _zAvailable from publisher's website |
| 999 |
_c30076559 _d30076559 |
||